Linklaters advises Union Acquisition Corp. II SPAC on US$1.125 billion business combination with Crynssen Pharma Group

Linklaters has advised Union Acquisition Corp. II (UAC II), a special purpose acquisition company (SPAC) on its agreement to combine with Crynssen Pharma Group Ltd (Procaps) to form a new holding company Procaps Group, S.A., which will be listed on Nasdaq under “PROC”. 

Procaps is a leading global pharmaceutical technology and healthcare company based in Latin America that has grown into a leading pharma company with a presence in 13 countries and reach in 50 markets with a wide portfolio of patents and trademarks. 

The transaction implies an enterprise value for the combined company of approximately US$1.125 billion. In connection with the transaction, UAC II also completed a US$100 million private investment in public equity (PIPE) offering. The cash raised in the PIPE, as well as the proceeds from the 2019 IPO of UAC II, will be used by the company to pursue growth opportunities, including M&A.

The transaction is the first Latin American SPAC to have an over-subscribed PIPE. It is also one of the few de-SPACs between a U.S.-listed SPAC and a Latin American business. It is subject to approval by the UAC II shareholders and other customary closing conditions and is expected to close during the third quarter of 2021.

The Linklaters team was led by partners Matthew Poulter, Jeffrey Cohen, and Scott Sonnenblick alongside senior associates Pierre-Emmanuel Perais and Burc Ozcelik, and counsel Matthew Brigham (Tax).

Linklaters offers industry-leading advice in M&A and capital markets transactions and is a destination for SPAC transactions. UAC II is the second SPAC from sponsor, Union Acquisition Group (UAG), which focuses on high-growth companies with business or entities in Latin America. It is also the second business combination involving UAG companies that Linklaters has advised on, previously advising Bioceres, in its initial business combination with Union Acquisition Corp.